In vitro and in vivo effect of hyaluronic acid modified, doxorubicin and gallic acid co-delivered lipid-polymeric hybrid nano-system for leukemia therapy

References

• O’Donnell MR, Tallman MS, Abboud CN, et al. Acute myeloid leukemia, version 3.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2017;15(7):926–957. doi:10.6004/jnccn.2017.011628687581
   PubMed Web of Science ®Google Scholar
• Deng R, Shen N, Yang Y, et al. Targeting epigenetic pathway with gold nanoparticles for acute myeloid leukemia therapy. Biomaterials. 2018;167:80–90. doi:10.1016/j.biomaterials.2018.03.01329554483
   PubMed Web of Science ®Google Scholar
• Mendes AN, Filgueiras LA, Siqueira MRP, et al. Encapsulation of Piper cabralanum (Piperaceae) nonpolar extract in poly(methyl methacrylate) by miniemulsion and evaluation of increase in the effectiveness of antileukemic activity in K562 cells. Int J Nanomedicine. 2017;12:8363–8373. doi:10.2147/IJN.S13475629200848
   PubMed Web of Science ®Google Scholar
• Faderl S, Kantarjian HM, Talpaz M. Chronic myelogenous leukemia: update on biology and treatment. Oncology (Williston Park). 1999;13(2):169–80; discussion 181, 184.
   PubMed Web of Science ®Google Scholar
• Tang R, Cohen S, Perrot JY, et al. P-gp activity is a critical resistance factor against AVE9633 and DM4 cytotoxicity in leukaemia cell lines, but not a major mechanism of chemoresistance in cells from acute myeloid leukaemia patients. BMC Cancer. 2009;9:199. doi:10.1186/1471-2407-9-19919549303
   PubMed Web of Science ®Google Scholar
• Zhang P, Li J, Ghazwani M, et al. Effective co-delivery of doxorubicin and dasatinib using a PEG-Fmoc nanocarriers for combination cancer chemotherapy. Biomaterials. 2015;67:104–114. doi:10.1016/j.biomaterials.2015.07.02726210177
   PubMed Web of Science ®Google Scholar
• Misra R, Sahoo SK. Coformulation of doxorubicin and curcumin in poly(D,L-lactide-co-glycolide) nanoparticles suppresses the development of multidrug resistance in K562 cells. Mol Pharm. 2011;8(3):852–866. doi:10.1021/mp100455h21480667
   PubMed Web of Science ®Google Scholar
• He Y, Su Z, Xue L, Xu H, Zhang C. Co-delivery of erlotinib and doxorubicin by pH-sensitive charge conversion nanocarrier for synergistic therapy. J Control Release. 2016;229:80–92. doi:10.1016/j.jconrel.2016.03.00126945977
   PubMed Web of Science ®Google Scholar
• Zhang Y, Yang C, Wang W, et al. Co-delivery of doxorubicin and curcumin by pH-sensitive prodrug nanoparticle for combination therapy of cancer. Sci Rep. 2016;6:21225. doi:10.1038/srep2122526876480
   PubMed Web of Science ®Google Scholar
• Li M, Tang Z, Lin J, et al. Synergistic antitumor effects of doxorubicin-loaded carboxymethyl cellulose nanoparticle in combination with endostar for effective treatment of non-small-cell lung cancer. Adv Healthc Mater. 2014;3(11):1877–1888. doi:10.1002/adhm.20140010824846434
   PubMed Web of Science ®Google Scholar
• Singh A, Fatima K, Srivastava A, et al. Anticancer activity of gallic acid template-based benzylidene indanone derivative as microtubule destabilizer. Chem Biol Drug Des. 2016;88(5):625–634. doi:10.1111/cbdd.1280527495835
   PubMed Web of Science ®Google Scholar
• Isuzugawa K, Inoue M, Ogihara Y. Ca2+-Dependent caspase activation by gallic acid derivatives. Biol Pharm Bull. 2001;24(7):844–847.11456129
   PubMed Web of Science ®Google Scholar
• Madlener S, Illmer C, Horvath Z, et al. Gallic acid inhibits ribonucleotide reductase and cyclooxygenases in human HL-60 promyelocytic leukemia cells. Cancer Lett. 2007;245(1–2):156–162. doi:10.1016/j.canlet.2006.01.00116488533
   PubMed Web of Science ®Google Scholar
• Chandramohan Reddy T, Bharat Reddy D, Aparna A, et al. Anti-leukemic effects of gallic acid on human leukemia K562 cells: downregulation of COX-2, inhibition of BCR/ABL kinase and NF-κB inactivation. Toxicol In Vitro. 2012;26(3):396–405. doi:10.1016/j.tiv.2011.12.01822245431
   PubMed Web of Science ®Google Scholar
• Gu R, Zhang M, Meng H, Xu D, Xie Y. Gallic acid targets acute myeloid leukemia via Akt/mTOR-dependent mitochondrial respiration inhibition. Biomed Pharmacother. 2018;105:491–497. doi:10.1016/j.biopha.2018.05.15829883944
   PubMed Web of Science ®Google Scholar
• Mayer LD, Harasym TO, Tardi PG, et al. Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice. Mol Cancer Ther. 2006;5(7):1854–1863. doi:10.1158/1535-7163.MCT-06-011816891472
   PubMed Web of Science ®Google Scholar
• Basha R, Sabnis N, Heym K, Bowman WP, Lacko AG. Targeted nanoparticles for pediatric leukemia therapy. Front Oncol. 2014;4:101. doi:10.3389/fonc.2014.0010124860784
   PubMedGoogle Scholar
• Termsarasab U, Yoon IS, Park JH, Moon HT, Cho HJ, Kim DD. Polyethylene glycol-modified arachidyl chitosan-based nanoparticles for prolonged blood circulation of doxorubicin. Int J Pharm. 2014;464(1–2):127–134. doi:10.1016/j.ijpharm.2014.01.01524451239
   PubMed Web of Science ®Google Scholar
• Ma P, Dong X, Swadley CL, et al. Development of idarubicin and doxorubicin solid lipid nanoparticles to overcome Pgp-mediated multiple drug resistance in leukemia. J Biomed Nanotechnol. 2009;5(2):151–161.20055093
   PubMed Web of Science ®Google Scholar
• Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007;2(12):751–760. doi:10.1038/nnano.2007.38718654426
   PubMed Web of Science ®Google Scholar
• Mooberry LK, Nair M, Paranjape S, McConathy WJ, Lacko AG. Receptor mediated uptake of paclitaxel from a synthetic high density lipoprotein nanocarrier. J Drug Target. 2010;18(1):53–58. doi:10.3109/1061186090315641919637935
   PubMed Web of Science ®Google Scholar
• Qiu J, Cheng R, Zhang J, et al. Glutathione-sensitive hyaluronic acid-mercaptopurine prodrug linked via carbonyl vinyl sulfide: a robust and CD44-targeted nanomedicine for leukemia. Biomacromolecules. 2017;18(10):3207–3214. doi:10.1021/acs.biomac.7b0084628835099
   PubMed Web of Science ®Google Scholar
• Zhong Y, Goltsche K, Cheng L, et al. Hyaluronic acid-shelled acid-activatable paclitaxel prodrug micelles effectively target and treat CD44-overexpressing human breast tumor xenografts in vivo. Biomaterials. 2016;84:250–261. doi:10.1016/j.biomaterials.2016.01.04926851390
   PubMed Web of Science ®Google Scholar
• Mandal B, Bhattacharjee H, Mittal N, et al. Core-shell-type lipid-polymer hybrid nanoparticles as a drug delivery platform. Nanomedicine. 2013;9(4):474–491. doi:10.1016/j.nano.2012.11.01023261500
   PubMed Web of Science ®Google Scholar
• Zhu B, Zhang H, Yu L. Novel transferrin modified and doxorubicin loaded Pluronic 85/lipid-polymeric nanoparticles for the treatment of leukemia: in vitroand in vivo therapeutic effect evaluation. Biomed Pharmacother. 2017;86:547–554. doi:10.1016/j.biopha.2016.11.12128024291
   PubMed Web of Science ®Google Scholar
• Yang F, Li A, Liu H, Zhang H. Gastric cancer combination therapy: synthesis of a hyaluronic acid and cisplatin containing lipid prodrug coloaded with sorafenib in a nanoparticulate system to exhibit enhanced anticancer efficacy and reduced toxicity. Drug Des Devel Ther. 2018;12:3321–3333. doi:10.2147/DDDT.S176879
   PubMed Web of Science ®Google Scholar
• Zhang L, Chan JM, Gu FX, et al. Self-assembled lipid–polymer hybrid nanoparticles: a robust drug delivery platform. ACS Nano. 2008;2(8):1696–1702. doi:10.1021/nn800275r19206374
   PubMed Web of Science ®Google Scholar
• Bi D, Zhao L, Yu R, et al. Surface modification of doxorubicin-loaded nanoparticles based on polydopamine with pH-sensitive property for tumor targeting therapy. Drug Deliv. 2018;25(1):564–575. doi:10.1080/10717544.2018.144044729457518
   PubMed Web of Science ®Google Scholar
• Guhagarkar SA, Majee SB, Samad A, Devarajan PV. Evaluation of pullulan-functionalized doxorubicin nanoparticles for asialoglycoprotein receptor-mediated uptake in Hep G2 cell line. Cancer Nanotechnol. 2011;2(1–6):49–55. doi:10.1007/s12645-011-0012-x26069484
   PubMedGoogle Scholar
• Daduang J, Palasap A, Daduang S, Boonsiri P, Suwannalert P, Limpaiboon T. Gallic acid enhancement of gold nanoparticle anticancer activity in cervical cancer cells. Asian Pac J Cancer Prev. 2015;16(1):169–174.25640346
   PubMedGoogle Scholar
• Tan S, Wang G. Lung cancer targeted therapy: folate and transferrin dual targeted, glutathione responsive nanocarriers for the delivery of cisplatin. Biomed Pharmacother. 2018;102:55–63. doi:10.1016/j.biopha.2018.03.04629549729
   PubMed Web of Science ®Google Scholar
• Song YF, Liu DZ, Cheng Y, et al. Charge reversible and mitochondria/nucleus dual target lipid hybrid nanoparticles to enhance antitumor activity of doxorubicin. Mol Pharm. 2018;15(3):1296–1308. doi:10.1021/acs.molpharmaceut.7b0110929432025
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhang P, Zhu T. Ovarian carcinoma biological nanotherapy: comparison of the advantages and drawbacks of lipid, polymeric, and hybrid nanoparticles for cisplatin delivery. Biomed Pharmacother. 2019;109:475–483. doi:10.1016/j.biopha.2018.10.15830399584
   PubMed Web of Science ®Google Scholar
• Zhang R, Ru Y, Gao Y, Li J, Mao S. Layer-by-layer nanoparticles co-loading gemcitabine and platinum (IV) prodrugs for synergistic combination therapy of lung cancer. Drug Des Devel Ther. 2017;11:2631–2642. doi:10.2147/DDDT.S143047
   PubMed Web of Science ®Google Scholar
• Wang G, Wang Z, Li C, et al. RGD peptide-modified, paclitaxel prodrug-based, dual-drugs loaded, and redox-sensitive lipid-polymer nanoparticles for the enhanced lung cancer therapy. Biomed Pharmacother. 2018;106:275–284. doi:10.1016/j.biopha.2018.06.13729966971
   PubMed Web of Science ®Google Scholar
• Li S, Wang L, Li N, Liu Y, Su H. Combination lung cancer chemotherapy: design of a pH-sensitive transferrin-PEG-Hz-lipid conjugate for the co-delivery of docetaxel and baicalin. Biomed Pharmacother. 2017;95:548–555. doi:10.1016/j.biopha.2017.08.09028869892
   PubMed Web of Science ®Google Scholar
• He P, Zhu X. Phospholipid-assisted synthesis of size-controlled gold nanoparticles. Mat Res Bul. 2007;42:1310–1315. doi:10.1016/j.materresbull.2006.10.014
   Web of Science ®Google Scholar
• Ma D, Lin QM, Zhang LM, Liang YY, Xue W. A star-shaped porphyrin-arginine functionalized poly(L-lysine) copolymer for photo-enhanced drug and gene co-delivery. Biomaterials. 2014;35:4357–4367. doi:10.1016/j.biomaterials.2014.01.07024576804
   PubMed Web of Science ®Google Scholar
• Balakrishnan P, Song CK, Jahn A, Cho HJ. Ceramide and N,N,N-trimethylphytosphingosine-iodide (TMP-I)-based lipid nanoparticles for cancer therapy. Pharm Res. 2016;33(1):206–216. doi:10.1007/s11095-015-1780-526337769
   PubMed Web of Science ®Google Scholar
• Gao Z, Li Z, Yan J, Wang P. Irinotecan and 5-fluorouracil-co-loaded, hyaluronic acid-modified layer-by-layer nanoparticles for targeted gastric carcinoma therapy. Drug Des Devel Ther. 2017;11:2595–2604. doi:10.2147/DDDT.S140797
   PubMed Web of Science ®Google Scholar
• Chou TC, Talalay P. Analysis of combined drug effects: a new look at a very old problem. Trends Pharmacol Sci. 1983;4:450–454. doi:10.1016/0165-6147(83)90490-X
   Web of Science ®Google Scholar
• Duan W, Liu Y. Targeted and synergistic therapy for hepatocellular carcinoma: monosaccharide modified lipid nanoparticles for the co-delivery of doxorubicin and sorafenib. Drug Des Devel Ther. 2018;12:2149–2161. doi:10.2147/DDDT.S166402
   PubMed Web of Science ®Google Scholar
• Culty M, O’Mara TE, Underhill CB, Yeager H Jr, Swartz RP. Hyaluronan receptor (CD44) expression and function in human peripheral blood monocytes and alveolar macrophages. J Leukoc Biol. 1994;56(5):605–611. doi:10.1002/jlb.56.5.6057525818
   PubMed Web of Science ®Google Scholar
• Li M, Fei X, Shi F, et al. Homoharringtonine delivered by high proportion PEG of long- circulating liposomes inhibits RPMI8226 multiple myeloma cells in vitro and in vivo. Am J Transl Res. 2016;8(3):1355–1368.27186264
   PubMed Web of Science ®Google Scholar
• Li W, Yi X, Liu X, Zhang Z, Fu Y, Gong T. Hyaluronic acid ion-pairing nanoparticles for targeted tumor therapy. J Control Release. 2016;225:170–182. doi:10.1016/j.jconrel.2016.01.04926826304
   PubMed Web of Science ®Google Scholar
• Kim CE, Lim SK, Kim JS. In vivo antitumor effect of cromolyn in PEGylated liposomes for pancreatic cancer. J Control Release. 2012;157(2):190–195. doi:10.1016/j.jconrel.2011.09.06621963773
   PubMed Web of Science ®Google Scholar